152 related articles for article (PubMed ID: 7799029)
1. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
Cascinu S; Cordella L; Del Ferro E; Fronzoni M; Catalano G
J Clin Oncol; 1995 Jan; 13(1):26-32. PubMed ID: 7799029
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
[TBL] [Abstract][Full Text] [Related]
3. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
Smyth JF; Bowman A; Perren T; Wilkinson P; Prescott RJ; Quinn KJ; Tedeschi M
Ann Oncol; 1997 Jun; 8(6):569-73. PubMed ID: 9261526
[TBL] [Abstract][Full Text] [Related]
4. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats.
Tredici G; Cavaletti G; Petruccioli MG; Fabbrica D; Tedeschi M; Venturino P
Neurotoxicology; 1994; 15(3):701-4. PubMed ID: 7854609
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.
Cascinu S; Fedeli A; Del Ferro E; Luzi Fedeli S; Catalano G
J Clin Oncol; 1994 May; 12(5):1058-62. PubMed ID: 8164030
[TBL] [Abstract][Full Text] [Related]
7. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats.
Hamers FP; Brakkee JH; Cavalletti E; Tedeschi M; Marmonti L; Pezzoni G; Neijt JP; Gispen WH
Cancer Res; 1993 Feb; 53(3):544-9. PubMed ID: 8425186
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
9. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Nakata B; Hirakawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
[TBL] [Abstract][Full Text] [Related]
11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
13. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant chemotherapy with combined S-1 plus weekly low-dose cisplatin followed by surgical resection for advanced gastric cancer].
Isobe T; Hashimoto K; Kizaki J; Miyagi M; Aoyagi K; Koufuji K; Shirouzu K
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1331-5. PubMed ID: 24105055
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of S-acyl glutathione 2% cream vs. placebo against UVB-induced erythema: a randomized, double-blinded clinical trial.
Grandi V; Milanesi N; Sessa M; Gola M; Cappugi P; Pimpinelli N
G Ital Dermatol Venereol; 2019 Dec; 154(6):632-637. PubMed ID: 28399620
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
Sato Y; Kondo H; Honda K; Takahari D; Sumiyoshi T; Tsuji Y; Yoshizaki N; Niitsu Y
Int J Clin Oncol; 2005 Feb; 10(1):40-4. PubMed ID: 15729600
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Ohtsu A; Shah MA; Van Cutsem E; Rha SY; Sawaki A; Park SR; Lim HY; Yamada Y; Wu J; Langer B; Starnawski M; Kang YK
J Clin Oncol; 2011 Oct; 29(30):3968-76. PubMed ID: 21844504
[TBL] [Abstract][Full Text] [Related]
19. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
20. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
Imada T; Sairenji M; Suda T; Yamamoto Y; Amano T; Motohashi H
Hepatogastroenterology; 1999; 46(25):594-600. PubMed ID: 10228867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
